Hina Takano
Overview
Explore the profile of Hina Takano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
221
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hosoya E, Ando J, Kinoshita S, Furukawa Y, Toyoshima Y, Azusawa Y, et al.
Haematologica
. 2024 Oct;
110(3):777-783.
PMID: 39415689
No abstract available.
2.
Misawa K, Yasuda H, Matsuda H, Hara M, Ochiai T, Koyama D, et al.
Intern Med
. 2022 Nov;
61(22):3421-3424.
PMID: 36385048
Immune checkpoint inhibitors (ICIs) are widely used for the treatment of various cancers. However, paradoxical exacerbation of neoplasms, referred to as "hyperprogressive disease," has been reported in a proportion of...
3.
Misawa K, Yasuda H, Koyama D, Inano T, Inoguchi A, Shirasu C, et al.
EJHaem
. 2022 Aug;
3(3):992-995.
PMID: 35941885
Paroxysmal cold hemoglobinuria (PCH) is an extremely rare subtype of autoimmune hemolytic anemia (AIHA) in adults. PCH is caused by the biphasic Donath-Landsteiner (DL) antibody which fixes complement to red...
4.
Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, et al.
Cancer Sci
. 2020 Jul;
111(8):2923-2934.
PMID: 32614159
This study presents the final report of the multicenter, prospective tyrosine kinase inhibitor discontinuation study, D-STOP, after a 3-year follow-up of 54 patients with chronic CML who discontinued dasatinib after...
5.
Nishijima A, Noguchi Y, Narukawa K, Takano H, Oshikawa G
Rinsho Ketsueki
. 2019 Nov;
60(10):1425-1430.
PMID: 31695002
A 70-year-old man was admitted to our hospital due to fever, lymphadenopathy, and leukocytosis. White blood cell count was 22,700/µl with 92% blastoid cells. Bone marrow examination revealed abnormal lymphoid...
6.
Yamashita T, Nishijima A, Noguchi Y, Narukawa K, Oshikawa G, Takano H
Clin Case Rep
. 2019 Mar;
7(2):316-321.
PMID: 30847197
The de novo myeloid sarcoma (MS) type of acute promyelocytic leukemia (APL) is rare, and clinical features may differ from extramedullary diseases in advanced APL. Many cases occur as a...
7.
Tanaka K, Toyota S, Akiyama M, Wakimoto N, Nakamura Y, Najima Y, et al.
Acta Haematol
. 2019 Feb;
141(2):111-118.
PMID: 30726834
We assessed the efficacy and safety of weekly cyclophosphamide-bortezomib-dexamethasone (CBD) induction prior to autologous stem cell transplantation (ASCT) in newly diagnosed Japanese patients with multiple myeloma (MM). This regimen consisted...
8.
Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, et al.
Cancer Sci
. 2017 Oct;
109(1):182-192.
PMID: 29058817
Tyrosine kinase inhibitors (TKI) improve the prognosis of patients with chronic myelogenous leukemia (CML) by inducing substantial deep molecular responses (DMR); some patients have successfully discontinued TKI therapy after maintaining...
9.
Iriyama N, Ohashi K, Hashino S, Kimura S, Nakaseko C, Takano H, et al.
Intern Med
. 2017 Oct;
57(1):17-23.
PMID: 29033428
Objective The aim of this study was to prospectively investigate the efficacy and safety profiles of low-dose dasatinib therapy (50 mg once daily). Methods Patients with chronic myeloid leukemia in...
10.
Shiseki M, Yoshida C, Takezako N, Ohwada A, Kumagai T, Nishiwaki K, et al.
Int J Clin Oncol
. 2017 May;
22(5):972-979.
PMID: 28550414
Background: With the introduction of imatinib, a first-generation tyrosine kinase inhibitor (TKI) to inhibit BCR-ABL1 kinase, the outcome of chronic-phase chronic myeloid leukemia (CP-CML) has improved dramatically. However, only a...